Article thumbnail

Allergologie: 2. Mastocytose systémique--nouvelles stratégies thérapeutiques [Systemic mastocytosis--new therapeutic strategies].

By C.M. Maniu, C. Ribi and F. Spertini

Abstract

Systemic mastocytosis is characterized by an excessive proliferation of mast cells and their accumulation in different organs. Avoidance of trigger factors leading to anaphylaxis is a general measure valid for all forms of mastocytosis. A premedication is necessary in case of surgery, anesthesia or administration of radiocontrast agents. Symptomatic treatment comprises antihistamines, anti-leukotrienes, proton pump inhibitors and topical corticosteroids. Indolent mastocytosis with refractory symptoms, the rare cases of aggressive mastocytosis with organ dysfunction and the even rarer mast cell leukemia require cytoreductive therapy. First-line agents are interferon alpha 2b and imatinib, a tyrosine kinase inhibitor. To date there is no curative treatment

Topics: Allergy and Immunology/trends; Anti-Inflammatory Agents/therapeutic use; Cladribine/therapeutic use; Humans; Interferon-alpha/therapeutic use; Mastocytosis, Systemic/diagnosis; Mastocytosis, Systemic/prevention & control; Medical Oncology/methods; Medical Oncology/trends; Protein Kinase Inhibitors/therapeutic use; Recombinant Proteins/therapeutic use; Therapies, Investigational/methods; Therapies, Investigational/trends
Year: 2013
OAI identifier: oai:serval.unil.ch:BIB_D8E4A67BD0EC
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://serval.unil.ch/notice/... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles